← Back to work
Works cited by this work
77 works
Work: Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler +36
Article20204 citationsABIDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi +35
Article20193 citationsABIEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin +9
Article20152 citationsABIDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca +17
Article20182 citationsABIDapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter +11
Article20202 citationsABIKEAP1‐NRF2 protein–protein interaction inhibitors: Design, pharmacological properties and therapeutic potential
Enrique Crisman, Pablo Duarte, E. Daudén +4
Review article20222 citationsABIA Comprehensive Guide to Sodium Glucose Cotransport Inhibitors
Christopher Cunningham, Ahmad Jabri, Laith Alhuneafat +1
Review article20232 citationsABICardiovascular prevention 2022. Russian national guidelines
S. А. Boytsov, Nana Pogosova, А. А. Аншелес +34
Article20232 citationsABIPharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials
Karan B. Bhanushali, Heena Asnani, Ambica Nair +2
Review article20242 citationsABI